On September 1, 2022 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John Butler, Chief Executive Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference (Press release, Akebia, SEP 1, 2022, View Source/news-releases/news-release-details/akebia-therapeutics-present-virtually-hc-wainwright-24th-annual" target="_blank" title="View Source/news-releases/news-release-details/akebia-therapeutics-present-virtually-hc-wainwright-24th-annual" rel="nofollow">View Source [SID1234618911]). The hybrid conference will take place September 12–14, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on-demand beginning September 12, 2022 through the Investors section of Akebia’s website at View Source for approximately 90 days.